Literature DB >> 2516324

The light-dark cycle modulates the effects of ritanserin on sleep-wakefulness patterns in the rat.

C Dugovic1, J E Leysen, P F Janssen, A Wauquier.   

Abstract

The 5-HT2 receptor antagonist ritanserin (0.63 mg/kg IP) produced differential effects on sleep-wakefulness patterns in rats when administered during the light or dark period: an increase in the duration of deep slow wave sleep at the expense of light slow wave sleep, paradoxical sleep and wakefulness when injected during the light period, and no major sleep alteration when given at dark onset. Since circadian variations in serotonin receptor density might modulate the sleep response, we examined the effects of ritanserin on sleep in rats exposed to continuous light for 10 days, and whether 5-HT2 receptors were affected in separate groups of rats exposed to similar conditions. No significant changes in the KD- and Bmax -values of various receptors were found. However, ritanserin produced greater effects in continuous light conditions than when given during the light period in the 12-hr light-dark condition. This suggests a possible role of 5-HT2 receptors in the organization of sleep when the environmental photoperiod is disturbed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2516324     DOI: 10.1016/0091-3057(89)90554-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  3 in total

1.  Effects of ritanserin and chlordiazepoxide on sleep-wakefulness alterations in rats following chronic cocaine treatment.

Authors:  C Dugovic; T F Meert; D Ashton; G H Clincke
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Triazolam-induced sleep in the rat: influence of prior sleep, circadian time, and light/dark cycles.

Authors:  D M Edgar; W F Seidel; W C Dement
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505.

Authors:  Sandor Kantor; Rita Jakus; Brigitta Balogh; Anita Benko; Gyorgy Bagdy
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.